Entero Therapeutics - Latiglutenase for Celiac Disease Management
Latiglutenase, known as IMGX003, is an orally administered formulation comprising two recombinant proteases specifically targeting gluten proteins. It works by breaking down these proteins into smaller, non-reactive fragments, offering an adjunctive measure to a gluten-free diet for managing celiac disease. This autoimmune disorder affects the small intestine and is triggered by dietary gluten found in grains like wheat, rye, and barley, leading to villous atrophy. While patients are typically advised to adhere to a lifelong gluten-free diet, inadvertent gluten consumption can still occur, causing symptoms and potentially severe health complications such as cancer or osteoporosis. The Phase 3 clinical trials for Latiglutenase are scheduled to start in late 2024, aiming for market release by 2027. This therapy could serve a significant need in the growing multimillion-dollar celiac disease sector, providing a new management option for those struggling with dietary restrictions.Entero Therapeutics is advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its three proprietary technologies – latiglutenase, a potentially first-in-class, Phase 3, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; Phase 2 capeserod, a selective 5-HT4 receptor partial agonist being developed for multiple gastrointestinal indications; and adrulipase, a Phase 2 a recombinant lipase designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency.
Entero Therapeutics is developing these technologies for a host of GI diseases where there are significant unmet clinical needs and limited therapeutic options, resulting in painful, life threatening and discomforting consequences for patients. Our goal is to help protect the health and restore quality of life for the millions of people afflicted.